Making a product is just an activity, making a profit on a product is the achievement.” ― Amit Kalantri, Wealth of Words
Few stocks have been as controversial in the biotech/biopharma space as La Jolla Pharmaceutical (LJPC). The stock remains down more than 75% since early-August, but has seen significant recent insider buying so far this year. The stock also has several potential 2019 catalysts. Here's a deeper look at this "battleground" stock.
Company Overview:
La Jolla Pharmaceutical is a San Diego-based pharmaceutical company with one approved drug and two in